A phenotypic mouse model of basaloid breast tumors

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Kim, Soyoung ^a   Roopra, Avtar ^b   Alexander, Caroline M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; DIMETHYLBENZ[A]ANTHRACENE; DOXORUBICIN; PROTEIN P53; TRANSCRIPTOME; VASCULOTROPIN; ANTHRACYCLINE; CARCINOGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL CELL CARCINOMA; BREAST TUMOR; CANCER STEM CELL; CELL ACTIVITY; CELL DIVISION; CELL FRACTIONATION; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; GENE MUTATION; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANIMAL; CELL SEPARATION; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; EXPERIMENTAL NEOPLASM; PATHOLOGY; VIRUS CULTURE;

ANIMALS; ANTHRACYCLINES; CARCINOGENS; CELL SEPARATION; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASTIC STEM CELLS; PHENOTYPE; SERIAL PASSAGE;

EID: 84863030315     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030979     Document Type: Article

References (65)

1. Foulkes WD, Smith IE, Reis-Filho JS, (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948.
2. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, et al. (2010) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol.
3. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, et al. (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376.
4. Rakha EA, Ellis IO, Reis-Filho JS, (2008) Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol 21: 1060-1061; author reply 1061-1062.
5. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, et al. (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65.
6. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, et al. (2007) Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 50: 434-438.
7. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, et al. (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15: 2302-2310.
8. Toft DJ, Cryns VL, Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol 25: 199-211.
9. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, et al. (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16: 214-218.
10. Turner NC, Reis-Filho JS, (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25: 5846-5853.
11. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, et al. (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109: 123-139.
12. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, et al. (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005-1010.
13. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, et al. (2011) Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. Clin Cancer Res 17: 1082-1089.
14. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, et al. (2010) A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 16: 6159-6168.
15. Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, et al. (2010) DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 123: 189-196.
16. Michalak EM, Jonkers J, (2010) Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer. J Mammary Gland Biol Neoplasia.
17. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, et al. (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439: 993-997.
18. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, et al. (2006) Generation of a functional mammary gland from a single stem cell. Nature 439: 84-88.
19. Zhang M, Atkinson RL, Rosen JM, (2010) Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci U S A 107: 3522-3527.
20. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, et al. (2009) Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 7: e1000121.
21. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783.
22. Lomonaco SL, Finniss S, Xiang C, Decarvalho A, Umansky F, et al. (2009) The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 125: 717-722.
23. Kunigal S, Lakka SS, Joseph P, Estes N, Rao JS, (2008) Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors. Clin Cancer Res 14: 3617-3626.
24. Mehta RG, (2000) Experimental basis for the prevention of breast cancer. Eur J Cancer 36: 1275-1282.
25. Badders NM, Goel S, Clark RJ, Klos KS, Kim S, et al. (2009) The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. PloS One 4: e6594.
26. Mote PA, Arnett-Mansfield RL, Gava N, deFazio A, Mulac-Jericevic B, et al. (2006) Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle. Endocrinology 147: 5503-5512.
27. McDermott SP, Ranheim EA, Leatherberry VS, Khwaja SS, Klos KS, et al. (2006) Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development. Oncogene.
28. Liu G, Bafico A, Harris VK, Aaronson SA, (2003) A novel mechanism for Wnt activation of canonical signaling through the LRP6 receptor. Mol Cell Biol 23: 5825-5835.
29. Alexander CM, Puchalski J, Klos KS, Badders N, Ailles L, et al. (2009) Separating stem cells by flow cytometry: reducing variability for solid tissues. Cell Stem Cell 5: 579-583.
30. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, et al. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8: R76.
31. Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, et al. (2007) Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene.
32. Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, et al. (2004) Somatic mutation of p53 leads to estrogen receptor alpha-positive and-negative mouse mammary tumors with high frequency of metastasis. Cancer Res 64: 3525-3532.
33. Mastroianni M, Kim S, Kim YC, Esch A, Wagner C, et al. (2009) Wnt signaling can substitute for estrogen to induce division of ERalpha-positive cells in a mouse mammary tumor model. Cancer Lett.
34. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, et al. (1999) Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126: 2739-2750.
35. Bade LK, Goldberg JE, Dehut HA, Hall MK, Schwertfeger KL, (2011) Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor. J Cell Sci 124: 3106-3117.
36. Pasic L, Eisinger-Mathason TS, Velayudhan BT, Moskaluk CA, Brenin DR, et al. (2011) Sustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissue. Genes Dev 25: 1641-1653.
37. Hochgrafe F, Zhang L, O'Toole SA, Browne BC, Pinese M, et al. (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res 70: 9391-9401.
38. Yan H, Blackburn AC, McLary SC, Tao L, Roberts AL, et al. (2010) Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice. Am J Pathol 176: 1421-1432.
39. Venkitaraman AR, (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182.
40. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907-913.
41. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, et al. (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13: 3989-3998.
42. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, et al. (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17: 1514-1520.
43. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, et al. (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161: 1991-1996.
44. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, et al. (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203: 661-671.
45. Bhargava R, Beriwal S, McManus K, Dabbs DJ, (2008) CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma. Am J Clin Pathol 130: 724-730.
46. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, et al. (2007) Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 104: 12111-12116.
47. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, et al. (2010) BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7: 403-417.
48. Kellen E, Vansant G, Christiaens MR, Neven P, Van Limbergen E, (2009) Lifestyle changes and breast cancer prognosis: a review. Breast Cancer Res Treat 114: 13-22.
49. Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, et al. (2005) Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol 33: 726-737.
50. Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL, (2007) Serial transplantation of NMU-induced rat mammary tumors: a model of human breast cancer progression. Int J Cancer 121: 474-485.
51. Jerry DJ, Butel JS, Donehower LA, Paulson EJ, Cochran C, et al. (1994) Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice. Mol Carcinog 9: 175-183.
52. Cardiff RD, Gumerlock PH, Soong M-M, Dandekar S, Barry PA, et al. (1988) c-H-ras-1 expression in 7,12-dimenthylbenzanthracene-induced Balb/c mouse mammary hyperplasias and their tumors. Oncogene 3: 205-213.
53. Collis SJ, DeWeese TL, Jeggo PA, Parker AR, (2005) The life and death of DNA-PK. Oncogene 24: 949-961.
54. Williams ES, Klingler R, Ponnaiya B, Hardt T, Schrock E, et al. (2009) Telomere dysfunction and DNA-PKcs deficiency: characterization and consequence. Cancer Res 69: 2100-2107.
55. Varela I, Klijn C, Stephens PJ, Mudie LJ, Stebbings L, et al. (2010) Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biol 11: R100.
56. Martin SA, Hewish M, Lord CJ, Ashworth A, (2009) Genomic instability and the selection of treatments for cancer. J Pathol.
57. Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, et al. (2010) Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. Cell Cycle 9: 3780-3791.
58. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, et al. (2008) Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 68: 3243-3250.
59. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, et al. (2008) The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 68: 7711-7717.
60. Kim S, Goel S, Alexander CM, (2011) Differentiation Generates Paracrine Cell Pairs that Maintain Basaloid Mouse Mammary Tumors: Proof of Concept. PLoS One 6.
61. Cho RW, Wang X, Diehn M, Shedden K, Chen GY, et al. (2008) Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 26: 364-371.
62. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, et al. (2008) Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 68: 4674-4682.
63. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334.
64. Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, et al. (2008) alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 111: 411-417.
65. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, et al. (2003) Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 100: 15901-15905.